Aridis Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Patzer Eric, was filed 28 Jun 2024.
Since the insiders bought
- -99.8%Entry US$0.06 · Close at T+365 US$0.00
- -99.8%Entry US$0.06 · Close at T+365 US$0.00
- -53.6%Entry US$4.12 · Close at T+365 US$1.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
- 714,286 shares@ US$0.0768.3% of flowCommon stock purchaseSEC:0001493152-24-025670:0Canonical exit: 22 Sept 2024 (T+90)
- 714,286 shares@ US$0.0768.7% of flowCommon stock purchaseSEC:0001493152-24-025672:0Canonical exit: 22 Sept 2024 (T+90)
- 15,000 sharesCommon StockSEC:0001493152-23-021481:0
- 5,000 sharesCommon StockSEC:0001493152-23-021483:0
- 12,000 sharesCommon StockSEC:0001493152-23-021487:0
- 10,000 sharesCommon StockSEC:0001493152-23-021476:0
- 5,000 sharesCommon StockSEC:0001493152-23-021478:0
- 4,000 sharesCommon StockSEC:0001493152-23-021470:0
- 1,991 shares@ US$4.15Common StockSEC:0001104659-21-113792:1Canonical exit: 6 Dec 2021 (T+90)
- 100 shares@ US$3.97Common StockSEC:0001104659-21-113792:2Canonical exit: 6 Dec 2021 (T+90)
- 3,009 shares@ US$4.15100.0% of flowCommon StockSEC:0001104659-21-113792:0Canonical exit: 2 Dec 2021 (T+90)
- 2,000 shares@ US$4.87100.0% of flowCommon StockSEC:0001104659-21-096534:0Canonical exit: 25 Oct 2021 (T+90)
- 5,000 shares@ US$5.1131.7% of flowCommon StockSEC:0001104659-21-096532:0Canonical exit: 25 Oct 2021 (T+90)
- 5,175 shares@ US$4.8431.3% of flowCommon StockSEC:0001104659-21-096531:0Canonical exit: 25 Oct 2021 (T+90)
- 16,000 shares0Common StockSEC:0001104659-21-025283:0
15 of 15 declarations
About Aridis Pharmaceuticals, Inc.
On June 24, 2024, two purchases of EUR 46,587 each were filed at Aridis Pharmaceuticals, Inc., by Vu Truong, CEO, and Eric Patzer, a director. They are the two largest in the record, ahead of EUR 21,610 by Vu Truong on July 27, 2021, the day 3 filers bought EUR 51,033 in total. Across the full history, 5 purchase filings are classed as clustered. In all, 8 purchases (6 with an amount) are worth EUR 154,720, with a median of EUR 21,397.
No sale is filed. Hasan Jafri, Chief Medical Officer, signs 4 filings of which 3 purchases, Eric Patzer 4 of which 2 purchases, Vu Truong 3 of which 2 purchases, John F. Hamilton, a director, 2 of which one purchase, and Susan Richards Windham-Bannister, a director, one. The rest of the record is 6 option exercises and one filing of another kind.
Read moreShow less
The 15 filings are published from February 18, 2021 to June 28, 2024: 7 in 2021, 6 in 2023 and 2 in 2024. The median publication delay is 5 days after the trade. This US health care company, listed on Nasdaq, has none of its capital held by insiders, and no filing falls within the last twelve months.
